Liraglutide vs Pal-GHK
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
LiraglutideSkin & CosmeticAnti-Aging & Longevity
Pal-GHK- Summary
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
- Half-Life
- ~13 hours (once-daily dosing)
- Extended (lipid depot in stratum corneum)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- Start 0.6 mg, titrate to 3 mg
- 0.005–0.1% in formulation
- Frequency
- Once daily
- Once or twice daily
- Key Benefits
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Stimulates collagen I and III synthesis in dermis
- Reduces the appearance of fine lines and wrinkles
- Improves skin elasticity and firmness
- Inhibits collagenase (MMP-1) to preserve existing collagen
- Enhances wound healing and skin repair
- Well-tolerated in anti-aging serums and creams
- Side Effects
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Generally very well-tolerated
- Rare skin irritation at very high concentrations
- Possible formulation-dependent comedogenicity
- Stacks With
- —
- —